ABBV Stock Analysis

Key Financial Metrics

📊Valuation

P/E Ratio
19.09
Forward P/E
16.36
P/S Ratio
1.31
P/B Ratio
5.45
EV/EBITDA
13.84
EV/Revenue
1.41
PEG Ratio
1.52

💰Profitability

Gross Margin
37.2%
Operating Margin
25.4%
Net Margin
18.9%
ROE
25.6%
ROA
8.8%
ROIC
16.4%

📈Growth

Revenue Growth (YoY)
5.9%
EPS Growth (YoY)
8.5%
FCF Growth
11.3%

🏦Financial Health

Debt/Equity
0.79
Current Ratio
1.44
Quick Ratio
1.16
Interest Coverage
12.73

💵Dividends

Dividend Yield
1.6%
Payout Ratio
30.5%
Dividend Growth
5.5%

📋Per Share

EPS
$26.85
Book Value/Share
$93.06
FCF/Share
$21.54
Revenue/Share
$96.66

Proprietary Model

Finlytics Score

Instant view of the current conviction score for ABBV, with component-level transparency.

Refreshing score...Loading live inputs

Pro Feature

Peer Comparison

Compare valuation, growth, margins, and Finlytics Score against the closest sector names.

Previewing 2 peers

🔒 See full peer comparison with Pro — $29/month

Upgrade to Pro

Company overview

About AbbVie Inc.

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Finlytics combines this business profile with an interactive DCF valuation, bear/base/bull intrinsic value scenarios, financial statements, peer comparison, and the Finlytics Score so investors can evaluate ABBV stock from multiple angles.

Finlytics Score
59/100
Trailing P/E
74.6
Revenue Growth
+10.2%
Market Cap
$468.2B

Price History

1Y Performance: -6.09%

Financial Statements

Reported fundamentals across filing periods

Revenue, margins, and earnings power across reported periods.

Positive changeNegative change

Annual filings

Loading statement history